Oncoimmunology

Article	Citations
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells	86
Ferroptosis: friend or foe in cancer immunotherapy?	83
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	73
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	53
Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity	52
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration	51
HIF2A mediates lineage transition to aggressive phenotype of cancer-associated fibroblasts in lung cancer brain metastasis	48
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients	48
A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy	46
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	45
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	45
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	43
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	40
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	39
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	39
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype	35
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	34
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway	34
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	34
The ART of tumor immune escape	33
Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties	32
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	32
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	32
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	30
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response	30

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	28
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint in	28
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	27
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 th immunorad conference	27
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma	26
Cellular senescence enhances adaptive anticancer immunosurveillance	26
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes	26
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	26
Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues	26
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy	26
MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 + T cells in vivo	25
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses	25
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma	25
Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance	25
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities	24
A mitochondrial checkpoint to adaptive anticancer immunity	24
Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma	24
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	24
HUNK as a key regulator of tumor-associated macrophages in triple negative breast cancer	24
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer	24
Group 2 innate lymphoid cells boost CD8 + T-cell activation in anti-tumor immune responses	24
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome	23
FGL2 172-220 peptides improve the antitumor effect of HCMV-IE1mut vaccine against glioblastoma by modulating immunosuppressive cells in the tumor microenvironment	23
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy	23
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	23
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	23
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	23
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies	22
Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death	22
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutan	22
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)	21
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells	21
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	21
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin	21
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	20
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	20
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	20
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	19
Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice	19
Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC	19
Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1	19
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors	19
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	19
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma	18
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	18
CXCL5-mediated accumulation of mature neutrophils in lung cancer tissues impairs the differentiation program of anticancer CD8 T cells and limits the efficacy of checkpoint inhibitors	18
Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness	17
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors	17
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	17
PDIA3 as a potential bridge between immunogenic cell death and autoreactivity	17

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1	17
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes	17
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	17
Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils	17
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system	16
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	16
Functional and molecular characterization of PD1 + tumor-infiltrating lymphocytes from lung cancer patients	16
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	16
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis	16
MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma	16
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	16
Deep learning using bulk RNA-seq data expands cell landscape identification in tumor microenvironment	16
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	16
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer	16
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	15
STING is significantly increased in high-grade glioma with high risk of recurrence	15
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	15
ADA/CD26 axis increases intra-tumor PD-1 + CD28 + CD8 + T-cell fitness and affects NSCLC progno	15
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	15
Human NK cells and cancer	15
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	15
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure	15
An oncogene regulating chromatin favors response to immunotherapy	14
FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population	14
Cell type-specific induction of ferroptosis to boost antitumor immunity	14
Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance	14
Trial watch: anticancer vaccination with dendritic cells	14
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	14
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade	14
The potential role of CMC1 as an immunometabolic checkpoint in T cell immunity	14
Memory-like differentiation enhances NK cell responses against colorectal cancer	13
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	13
CD39 + conventional CD4 + T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade	13
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	13
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment	12
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models	12
An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells	12
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy	12
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy	12
Tumor-infiltrating lymphocytes for melanoma immunotherapy	12
IL-15 transpresentation by ovarian cancer cells improves CD34 + progenitor-derived NK cell's anti-tumor functionality	11
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	11
Association between immune-related adverse event timing and treatment outcomes	11
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA	11
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles	11
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor	11
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	11
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors	11
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	11
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	11
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma	11
Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system	11
Enriched circulating and tumor-resident TGF-β + regulatory B cells in patients with melanoma promote FOXP3 + Tregs	11
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome	11
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer	11
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6 th annual ImmunoRad conference	10
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells	10
Piezo1 facilitates optimal T cell activation during tumor challenge	10
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors	10
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	10
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	10
Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression	10
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	10
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	10
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	10
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells	10
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma	10
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	10
Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression	10
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer	10
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	10
A nanoparticle-based tour de force for enhancing immunogenic cell death elicited by photodynamic therapy	10
Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2 , and CD44 through NFκB-signal	10
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	10
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	10
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	10
Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer	9
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab	9
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy	9
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	9

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade	9
Assessment of adenosinergic activity of small extracellular vesicles in plasma of cancer patients and healthy donors	9
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	9
Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors	9
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer	9
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	9
Mammary carcinoma: toward a realistic mouse model of incurable cancers	9
CD8 T cell-mediated depletion of HBV surface-antigen-expressing, bilineal-differentiated liver carcinoma cells generates highly aggressive escape variants	9
Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma	8
Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy	8
Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells	8
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	8
C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer	8
Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance	8
CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non	8
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism	8
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	8
Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis	8
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition	8
Identification of RNA-binding protein hnRNP C targeting the 3’UTR of the TAP-associated glycoprotein tapasin in melanoma	8
Arsenic trioxide as an inducer of immunogenic cell death	8
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	8
Identification and characterization of the anti-viral interferon lambda 3 as direct target of the Epstein-Barr virus microRNA-BART7-3p	8
Trial watch: local anesthetics in cancer therapy	8
Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs	8
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	8
CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent	8
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors	8
CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response	8
Non-pharmaceutical interventions to optimize cancer immunotherapy	8
Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma	8
Immunogenic oncolysis by tigilanol tiglate	7
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	7
Bystander CD4 + T cells infiltrate human tumors and are phenotypically distinct	7
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma	7
An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis	7
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	7
Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade	7
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology	7
BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells	7
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer	7
Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response	7
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer	7
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	7
Immune sunrise: from the immunome to the cancer immune landscape	7
Is ferroptosis immunogenic? The devil is in the details!	7
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation	6
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer	6
Translocation of Helicobacter hepaticus synergizes with myeloid-derived suppressor cells and contributes to breast carcinogenesis	6
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	6
Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma	6
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors	6
Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma	6
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies	6
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors	6
Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma	6
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients	6
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	6
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment	6
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients	6
Reprogramming monocyte-derived macrophages through caspase inhibition	6
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1	5
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)	5
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	5
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism	5
FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer	5
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	5
Interleukin-17 signaling influences CD8 + T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells	5
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade	5
Immunological responses to adjuvant vaccination with combined CD1c + myeloid and plasmacytoid dendritic cells in stage III melanoma patients	5
S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs	5
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer	5
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	5
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer	5
Humanized mouse models of KRAS -mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies	5
Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients	5
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	5
Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes	5
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients	5
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma	5
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression	5
Paradoxical control of multifocal mammary oncogenesis by radiation therapy	5
Trial watch: beta-blockers in cancer therapy	5
Mixed cryoglobulinemia decelerates hepatocellular carcinoma development in hepatitis C patients with SVR by downregulating regulatory B cells: a 12-year prospective cohort study	5
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy	5